BioPhorum to expand its collaborations in Asia
BioPhorum collaborations are successful because industry leaders and experts pool their knowledge, practices and ideas. So it makes sense that the more global the input, the better the collaborative effort and the stronger the BioPhorum outputs.
In October, Simon Chalk, Tony White and Neil Richards from BioPhorum will travel to Asia to meet with existing and potential members of the BioPhorum community.
The trip is being hosted by MedCity, which promotes the world-leading life sciences cluster in London, and it is running the delegation for the UK Government’s Department for International Trade. The BioPhorum team will spend the first week in Japan attending a series of meetings:
- 7 October, Kobe – symposium hosted by Japan’s Foundation for Biomedical Research and Innovation
- 8 October, Tokyo – symposium at the Nihonbashi Centre
- 9–11 October, Yokohama – BioJapan conference, an event for the global biotechnology industry, during which Simon will present a summary of his article on Applying GMPs to the BioPharma Supply Chain that was published by BioPharm International.
The BioJapan conference will have a ‘partnering facility’ to allow attendees to arrange face-to-face meetings with each other. If you would like to meet with the BioPhorum team, please feel free to arrange this through the partnering program or email Neil Richards on email@example.com
The team will then move to South Korea and attend a symposium in Seoul on 14 October hosted by Korea Pharmaceutical and Bio-Pharma Manufacturers Association at the Seoul BioHub
Simon will return to Japan to continue planning the BioPhorum 2020 event, which takes place in Tokyo in May next year. Look out for more details of this event in future newsletters.
BioPhorum collaborations have been strengthened with the input from Asian companies, which have similarly benefited from the process. An example is Japanese pharmaceutical and biotechnology company Kyowa Kirin Co. (KKC), which joined the BioPhorum Development Group in 2017. It has been involved in discussions including process intensification, the novel process performance qualification approach and clinical-relevant specifications.
Discussing monoclonal and small-scale qualification activities, Katsuyoshi Yamazaki of KKC said, “It was good that we were able to participate in the face-to-face discussions as well as the workstream events. These are the critical topics that the authorities are interested in. Being able to ask specific questions via AskBPOG of companies that are mainly engaged in development in Europe and the US has a large benefit.”
There is a lot of biopharmaceutical activity and expertise in Asia and so increasing BioPhorum’s reach in the region will only help to make it an even stronger vehicle for change.